CXCL1 and chronic obstructive pulmonary disease: Finally, we showed that blocking the IL-36R by treating SAF with either recombinant IL-36Ra or an IL-36R blocking antibody reduced CXCL1 release from these cells when stimulated with media from poly(I:C)-stimulated COPD SAEC.